Deal boosts gene-editing technology aiming to cure Type 1 diabetes
In the latest move towards finding a stem cell-based cure for Type 1 diabetes, American company Vertex has announced a new agreement with CRISPR Therapeutics
In the latest move towards finding a stem cell-based cure for Type 1 diabetes, American company Vertex has announced a new agreement with CRISPR Therapeutics